“…In a comprehensive, long-term (up to 9 months post primary vaccination), experimental vaccination study using male Syrian hamsters, we evaluate neutralizing antibody responses and efficacy against BA.5 challenge after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a homologous or heterologous booster with mRNA-1273 (Moderna) or NVX-CoV2373 (Novavax). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Results The knowledge of the responders for each vaccine is as follows: Pfizer-BioNTech, 96.1%; AstraZeneca-Oxford, 66.1%; Moderna, 56.9%; and Johnson & Johnson's Janssen, 18.2%. A small percentage of responders (5.7%) believe that COVID-19 vaccination may alter their DNA, while 70% believe it can prevent them from getting sick with COVID-19 infection. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Methods: Patients with chronic conditions were recruited through Janssen’s Patient Engagement Research Council program. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Rivastigmine (Exelon(®), Novartis Basel—Switzerland) is a slowly reversible inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil (Aricept(®), Pfizer, New York, USA) and galantamine (Reminyl(®), Janssen, New Jersey,USA) show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible inhibitors. …”
Enlace del recurso
Enlace del recurso

“…While SGLT2i exhibit reduced efficacy in later stages, they exhibit nephroprotective effects in early stages of renal impairment. Funding: Janssen India (Pharmaceutical division of Johnson & Johnson).…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DECLARATION OF INTEREST: J.H. has received lecture honoraria as part of continuing medical education programmes sponsored by Novartis, Eli Lilly and Company, and Janssen-Cilag. COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2016. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DECLARATION OF INTERESTS: L.P. received speaker fees from Otsuka Canada and educational grant from Janssen Canada in 2017. COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2017. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In conclusion, data of the current study indicate that the sarcopenic state might interfere in the association among hypertension and poor cognitive status, once a higher frequency of hypertensive patients with low lower limb muscle function (i.e., SPPB and sit-to-stand) and muscle mass index (i.e., Janssen index) was observed in the <24 MMSE segment, in comparison with hypertensive patients with normal results in these parameters.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DECLARATION OF INTEREST: F.G. has received support or honoraria for CME, advisory work and lectures from Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Roche, and Sunovion, and has a family member with professional links to Lilly and GSK, including shares.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…FUNDING: The Rapid Service Fee was funded by Janssen KK.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Finally, the Ad26.COV2.S vaccine by Janssen Pharmaceuticals shows promise as a single-dose vaccine with a potential durability of response.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A sample of 578 employees completed the Stress Questionnaire, the Janssen’s nine-item scale and a single-item regarding absenteeism. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Vaccine-induced immune thrombotic thrombocytopenia (VITT) (also termed thrombosis with thrombocytopenia syndrome or vaccine-induced thrombotic thrombocytopenia or vaccine-induced immune thrombocytopenia) is characterized by (i) venous or arterial thrombosis; (ii) mild-to-severe thrombocytopenia; (iii) positive antiplatelet factor 4 (PF4)–polyanion antibodies or anti-PF4–heparin antibodies detected by the HIT (heparin-induced thrombocytopenia) ELISA; (iv) occurring 5–30 days after ChAdOx1 nCoV-19 (AstraZeneca) or Ad26.COV2.S (Johnson & Johnson/Janssen) vaccination. VITT’s incidence is 1 per 100 000 vaccinated people irrespective of age and up to 1 in 50 000 for people <50 years of age with the AstraZeneca COVID-19 vaccine. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…While generally safe and effective, rare cases of venous thromboembolism (VTE) have been reported after two adenovirus-based vaccines, the AstraZeneca ChAdOx1 nCoV-19 vaccine and the Janssen Ad.26.COV2.S vaccine, as well as after the Pfizer-BioNTech BNT162b2 mRNA vaccine. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…• Actualmente se están administrando cuatro vacunas en España con dos tecnologías diferentes: ARNm (Comirnaty y Moderna) y de vectores (Vaxzevria y Janssen). • Se habían administrado hasta junio de 2021 más de 38 millones de dosis y 15 millones de ciudadanos tenían la pauta vacunal completa. • Las vacunas han demostrado en los ensayos clínicos ser eficaces tanto para prevenir la infección como la hospitalización y el fallecimiento. • Los datos más concluyentes de su efectividad son en población mayor de 65 años ingresados en residencias. • Aún no disponemos de información para conocer la efectividad vacunal en otros segmentos poblacionales. • En general, las vacunas son seguras, aunque aparecen efectos adversos poco frecuentes, pero potencialmente graves, que requieren alta sospecha clínica y seguimiento: síndrome trombosis-trombocitopenia, síndrome de fuga capilar, miocarditis, cuadros anafilácticos, adenopatías. • Los sanitarios tienen un papel fundamental en la aceptabilidad y seguridad vacunal por la sospecha y notificación de posibles efectos adversos y la información dada a la ciudadanía.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The present review will discuss the four vaccines, AZD1222 (AstraZeneca or Vaxzevria), Janssen (Ad26.COV2.S), Moderna/mRNA-1273 and BioNTech/Fosun/Pfizer BNT162b1, that are currently in use worldwide to understand their efficacy, but also evaluate the difficulties and challenges of vaccine development. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Therefore, vaccine developers, including Moderna, BioNTech, Janssen, Inovio, and Gamaleya also filed patent applications for the protection of their vaccines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This review focusses on age-associated aspects of COVID-19 vaccines and vaccination strategies, and summarizes data on immunogenicity, efficacy and effectiveness of the four COVID-19 vaccines, which are licensed in the US and/or Europe; namely, the two mRNA vaccines by BioNTech/Pfizer (BNT162b2) and Moderna (mRNA-1273), and the adenovector vaccines developed by AstraZeneca/University Oxford (ChAdOx1-nCoV-19, AZD1222) and Janssen/Johnson&Johnson (Ad26.COV2-S), respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The physical activity mediated Demand-Control (pamDC) model (Häusser & Mojzisch, 2017, https://doi.org/10.1080/02678373.2017.1303759) combines these health indicators in a new theoretical framework. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…It has been associated with 2 adenovirus vector COVID-19 vaccines: ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Janssen). Unlike the myriad of other conditions that cause thrombosis and thrombocytopenia, VITT has an important distinguishing feature: affected individuals have platelet activating anti-PF4 antibodies that appear in a predictable time frame following vaccination. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso